Abstract
Squamous cell carcinomas of the head and neck are the sixth most frequently occurring cancers and the seventh leading cause of cancer-related deaths worldwide. Epigenetic alteration, using promoter hypermethylation of hMLH1 gene, is important for the development of head and neck squamous cell carcinoma (HNSCC).
Aim of this Work
The aim of the present study is to analyze the relationship between protein expression and promoter hypermethylation of the hMLH1 gene in HNSCC and correlating inactivation of this gene with clinical parameters.
Materials and Methods
Paired normal and tumor specimens from 49 patients with HNSCC were collected from Otolaryngology Department, Minia University Hospital, from 2006 to 2009. We analyzed hMLH1 protein expression and promoter hypermethylation by immunohistochemical and methylation-specific polymerase chain reaction (MSP).
Results
Decreased hMLH1 protein expression and hMLH1 promoter hypermethylation were shown in 15 (30.6%) and 14 (28.6%) cases, respectively. Eleven cases showed dysplasia and or carcinoma in situ in the surface squamous epithelia, and all were positively stained for the hMLH1 protein. hMLH1 promoter hypermethylation was detected in 10 (20.4%) cases of normal-appearing squamous mucosa adjacent to invasive carcinoma. Thirteen (86.7%) of 15 cases that were negative for the hMLH1 protein showed promoter hypermethylation, whereas 33 (97%) of 34 cases positive for the protein were negative of promoter methylation. Promoter hypermethylation was detected in 1 (7.1%) case in which invasive tumor cells were moderately positive for the hMLH1 protein. No significant correlation was observed between hMLH1 protein expression or hMLH1 promoter hypermethylation and any of clinicopathologic parameters.
Conclusions
hMLH1 gene may be detected early in head and neck squamous carcinogenesis. Promoter hypermethylation is an important mechanism for hMLH1 gene inactivation in HNSCC.
1
Introduction
In Egypt, head and neck cancer represents 17% of all malignant tumors. The median age of patients is 50 years, with male predominance of 3:1 . Squamous cell carcinomas of the head and neck (SCCHN), including those of the oral cavity, pharynx, and larynx, are the sixth most frequently occurring cancers and the seventh leading cause of cancer-related deaths worldwide , with tobacco habits, alcohol consumption, and human papillomavirus infection being the major risk factors for this type of cancer .
Epigenetic alterations together with accumulation of genetic aberrations have been established in SCCHN. Promoter CpG island hypermethylation may represent an attractive alternative mechanism for inactivation of the hMLH1 gene in head and neck squamous cell carcinoma (HNSCC). It was reported that methylation of CpG-rich islands is an important epigenetic mechanism by which multiple genes are inactivated . Increasing evidence indicates that promoter CpG island hypermethylation is associated with transcriptional silencing of genes and is stably inherited through mitosis in cancer . Thus, aberrant promoter hypermethylation is proved to be an important mechanism that can be used as a marker for SCCHN. Furthermore, because this epigenetic mechanism is potentially reversible, it can be targeted for therapeutic intervention .
It has been shown that loss of activity of some key genes may occur through epigenetic means . Loss of gene function by transcriptional silencing of selected genes may play a crucial role in the development and progression of sporadic human tumors .
DNA repair genes are also inactivated by the process of promoter hypermethylation during carcinogenesis. The mismatch DNA repair gene human MutL homologue 1 ( hMLH1 ) is inactivated by promoter hypermethylation in numerous human tumors . The epigenetic inactivation via promoter hypermethylation of hMLH1 gene 19 was mapped to a chromosome region 3p21.3-23 , has been linked to increased microsatellite instability in sporadic colorectal cancers and hereditary nonpolyposis colorectal cancer .
Promoter hypermethylation of the hMLH1 gene has also been reported in certain SCCHN. The inactivation of the hMLH1 gene by this mechanism has been implicated in SCCHN progression but not tumor initiation .
Promoter hypermethylation of the hMLH1 gene has been demonstrated in multiple tumor types, including HNSCC , lung cancer , gastric , colorectal , esophageal carcinoma , and ovarian cancers .
The present study aims to analyze the relationship between protein expression and promoter hypermethylation of the hMLH1 gene in HNSCC and correlating inactivation of this gene with clinical parameters.
2
Materials and methods
2.1
Patients and tissue specimens
Paired normal and tumor specimens from 49 patients with HNSCC were collected from 2006 to 2009 from freshly operated tumor and adjacent normal tissues from patients who underwent surgery before receiving any treatment from Otolaryngology Department, Minia University Hospital, Minia, Egypt.
For all 49 cases, tissue sections were fixed in 10% formalin, processed, embedded in paraffin, sectioned at 5- μ m thickness, and stained with hematoxylin and eosin for their diagnosis and to select the most representative sections for immunohistochemical (IHC) staining and DNA extraction.
The mean (SD) age of the patients at surgery was 57.85 (8.5) years (range, 40–79 years), and 45 patients were male, whereas 4 were female. The primary sites of the carcinomas were oral cavity (n = 19), pharynx (n = 4), and larynx (n = 26). Tumor sizes according to the TNM classification were T1 (n = 8), T2 (n = 12), T3 (n = 9), and T4 (n = 20). Lymph node metastasis was present in 32 cases. Characteristics of the patients are presented in Table (1 ).
Clinicopathologic features | No. of patients | % |
---|---|---|
Age (y) | ||
<50 | 15 | 30.6 |
≥50 | 34 | 69.4 |
Sex | ||
Male | 45 | 91.8 |
Female | 4 | 8.2 |
Tobacco habit | ||
Yes | 35 | 71.4 |
No | 14 | 28.6 |
Tumor site | ||
Oral cavity | 19 | 38.8 |
Pharynx | 4 | 8.1 |
Larynx | 26 | 53.1 |
Tumor stage | ||
T1 | 8 | 16.3 |
T2 | 12 | 24.5 |
T3 | 9 | 18.4 |
T4 | 20 | 40.8 |
N stage | ||
N0 | 17 | 34.7 |
N1 | 7 | 14.3 |
N2 | 16 | 32.7 |
N3 | 9 | 18.4 |
Clinical stage | ||
I | 8 | 16.3 |
II | 8 | 16.3 |
III | 9 | 18.4 |
IV | 24 | 49 |
2.2
IHC staining
Formalin-fixed, paraffin-embedded tissue sections were cut at 5- μ m for IHC staining by using a monoclonal antibody against hMLH1 protein (Clone ES05, Ready-to-Use; DAKO, Egypt). The standard avidin-biotin-peroxidase technique was used in this study. Antigen retrieval with microwave treatment was used in immunostaining. The normal squamous epithelia were used as internal positive controls.
2.3
Assessment of IHC staining
The hMLH1 IHC staining results were assessed semiquantitatively as previously described . The results are as follows: less than 10% positive cells being negative (−), 10% to 20% positive cells being mostly negative (+/−), 30% to 40% positive cells being weakly positive (+), 50% to 70% positive cells being moderately positive (++), 70% to 90% being strongly positive (+++), and more than 90% positive cells being very strongly positive (++++).
2.4
Tissue and DNA samples for molecular studies
DNA samples were collected from 5 deparaffinized, 5- μ m-thick tissue sections from each tissue block. Blood DNA was used as a positive control, and water was served as a negative control. Sections were stained with hematoxylin-eosin to verify their diagnosis. DNA was isolated by phenol/chloroform extraction after overnight incubation, with proteinase K at 37°C. DNA was extracted by the standard procedure of proteinase K digestion.
2.5
Bisulfite treatment
DNA was extracted from paired tumor and nearby normal tissue of each patient. DNA from paraffin-embedded tissue was extracted as described previously. The genomic DNA previously isolated was precipitated with 250 mmol/L NaCl and isopropanol. Then the extracted DNA (0.25–1 μ g) was treated with sodium bisulfite; because of the small amount of DNA isolated from the paraffin-embedded tissue samples, this step was performed according to a modified version of a previously described protocol . MSP distinguishes unmethylated from hypermethylated alleles in a given gene based on sequence changes produced after bisulfite treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil, and subsequent PCR using primers specific to either methylated or unmethylated DNA .
2.6
Promoter methylation assay for hMLH1
Amplification of promoter region of the hMLH1 gene is carried out in a Touchgene Gradient Thermal Cycler (Techne Inc, Princeton, NJ) in 50 µL PCR reaction mixture containing 2 µL of bisulfite-treated genomic DNA, dNTPs (each at 200 µmol/L), primers (50 pmol each per reaction), 2.5 mmol/L MgCl 2 , and 1.25 units Hotstar Taq (Qiagen, Valencia, CA) in 1× PCR buffer. All reagents are supplied with the Qiagen Hotstar Taq Kit (Qiagen), except for the dNTP mix (Roche Molecular Biochemicals, Giza, Egypt). Primer sequences of hMLH1 for the unmethylated reaction are 5′-TTT TGA TGT AGA TGT TTT ATT AGG GTT GT-3′ (sense) and 5′-ACC ACC TCA TCA TAA CTA CCC ACA-3′ (antisense), and for the methylated reaction, they are 5′-ACG TAG ACG TTT TAT TAG GGT CGC-3′ (sense) and 5′-CCT CAT CGT AAC TAC CCG CG-3′ (antisense) as described previously .
The PCR conditions are similar, except for the annealing temperature for both methylated and unmethylated reactions: initial degeneration and hot start at 95°C for 15 minutes, then 40 cycles consisting of 30 seconds at 95°C, 30 seconds at 63°C (methylated reactions) or 60°C (unmethylated reactions), and 1 minute at 72°C, followed by a final 5-minute extension at 72°C. Positive and negative control DNA samples and control without DNA (dH 2 O) was included for each set of PCR reactions.
The bisulfite-modified human placental DNA (Sigma, Egyptial International Center for Import Cairo, Egypt) and CpGenome universal methylated human DNA (Intergen Co, New York, NY) served as negative and positive control, respectively. The PCR products were separated with 2.2% agarose gel electrophoresis and visualized with 0.1% ethidium bromide staining.
2.7
Statistical analysis
Statistical analyses were performed using the SPSS version 17 for Windows (SPSS Inc, Chicago, IL) program package. The 2-sided χ 2 test was used to compare categorical variables, if the sample size was large. Fischer exact test was used when the sample size was small; such test was used when comparing the associations of hMLH1 immunoreactivity with age and sex. P ≤ .05 was used as a significance criterion.
2
Materials and methods
2.1
Patients and tissue specimens
Paired normal and tumor specimens from 49 patients with HNSCC were collected from 2006 to 2009 from freshly operated tumor and adjacent normal tissues from patients who underwent surgery before receiving any treatment from Otolaryngology Department, Minia University Hospital, Minia, Egypt.
For all 49 cases, tissue sections were fixed in 10% formalin, processed, embedded in paraffin, sectioned at 5- μ m thickness, and stained with hematoxylin and eosin for their diagnosis and to select the most representative sections for immunohistochemical (IHC) staining and DNA extraction.
The mean (SD) age of the patients at surgery was 57.85 (8.5) years (range, 40–79 years), and 45 patients were male, whereas 4 were female. The primary sites of the carcinomas were oral cavity (n = 19), pharynx (n = 4), and larynx (n = 26). Tumor sizes according to the TNM classification were T1 (n = 8), T2 (n = 12), T3 (n = 9), and T4 (n = 20). Lymph node metastasis was present in 32 cases. Characteristics of the patients are presented in Table (1 ).
Clinicopathologic features | No. of patients | % |
---|---|---|
Age (y) | ||
<50 | 15 | 30.6 |
≥50 | 34 | 69.4 |
Sex | ||
Male | 45 | 91.8 |
Female | 4 | 8.2 |
Tobacco habit | ||
Yes | 35 | 71.4 |
No | 14 | 28.6 |
Tumor site | ||
Oral cavity | 19 | 38.8 |
Pharynx | 4 | 8.1 |
Larynx | 26 | 53.1 |
Tumor stage | ||
T1 | 8 | 16.3 |
T2 | 12 | 24.5 |
T3 | 9 | 18.4 |
T4 | 20 | 40.8 |
N stage | ||
N0 | 17 | 34.7 |
N1 | 7 | 14.3 |
N2 | 16 | 32.7 |
N3 | 9 | 18.4 |
Clinical stage | ||
I | 8 | 16.3 |
II | 8 | 16.3 |
III | 9 | 18.4 |
IV | 24 | 49 |
2.2
IHC staining
Formalin-fixed, paraffin-embedded tissue sections were cut at 5- μ m for IHC staining by using a monoclonal antibody against hMLH1 protein (Clone ES05, Ready-to-Use; DAKO, Egypt). The standard avidin-biotin-peroxidase technique was used in this study. Antigen retrieval with microwave treatment was used in immunostaining. The normal squamous epithelia were used as internal positive controls.
2.3
Assessment of IHC staining
The hMLH1 IHC staining results were assessed semiquantitatively as previously described . The results are as follows: less than 10% positive cells being negative (−), 10% to 20% positive cells being mostly negative (+/−), 30% to 40% positive cells being weakly positive (+), 50% to 70% positive cells being moderately positive (++), 70% to 90% being strongly positive (+++), and more than 90% positive cells being very strongly positive (++++).
2.4
Tissue and DNA samples for molecular studies
DNA samples were collected from 5 deparaffinized, 5- μ m-thick tissue sections from each tissue block. Blood DNA was used as a positive control, and water was served as a negative control. Sections were stained with hematoxylin-eosin to verify their diagnosis. DNA was isolated by phenol/chloroform extraction after overnight incubation, with proteinase K at 37°C. DNA was extracted by the standard procedure of proteinase K digestion.
2.5
Bisulfite treatment
DNA was extracted from paired tumor and nearby normal tissue of each patient. DNA from paraffin-embedded tissue was extracted as described previously. The genomic DNA previously isolated was precipitated with 250 mmol/L NaCl and isopropanol. Then the extracted DNA (0.25–1 μ g) was treated with sodium bisulfite; because of the small amount of DNA isolated from the paraffin-embedded tissue samples, this step was performed according to a modified version of a previously described protocol . MSP distinguishes unmethylated from hypermethylated alleles in a given gene based on sequence changes produced after bisulfite treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil, and subsequent PCR using primers specific to either methylated or unmethylated DNA .
2.6
Promoter methylation assay for hMLH1
Amplification of promoter region of the hMLH1 gene is carried out in a Touchgene Gradient Thermal Cycler (Techne Inc, Princeton, NJ) in 50 µL PCR reaction mixture containing 2 µL of bisulfite-treated genomic DNA, dNTPs (each at 200 µmol/L), primers (50 pmol each per reaction), 2.5 mmol/L MgCl 2 , and 1.25 units Hotstar Taq (Qiagen, Valencia, CA) in 1× PCR buffer. All reagents are supplied with the Qiagen Hotstar Taq Kit (Qiagen), except for the dNTP mix (Roche Molecular Biochemicals, Giza, Egypt). Primer sequences of hMLH1 for the unmethylated reaction are 5′-TTT TGA TGT AGA TGT TTT ATT AGG GTT GT-3′ (sense) and 5′-ACC ACC TCA TCA TAA CTA CCC ACA-3′ (antisense), and for the methylated reaction, they are 5′-ACG TAG ACG TTT TAT TAG GGT CGC-3′ (sense) and 5′-CCT CAT CGT AAC TAC CCG CG-3′ (antisense) as described previously .
The PCR conditions are similar, except for the annealing temperature for both methylated and unmethylated reactions: initial degeneration and hot start at 95°C for 15 minutes, then 40 cycles consisting of 30 seconds at 95°C, 30 seconds at 63°C (methylated reactions) or 60°C (unmethylated reactions), and 1 minute at 72°C, followed by a final 5-minute extension at 72°C. Positive and negative control DNA samples and control without DNA (dH 2 O) was included for each set of PCR reactions.
The bisulfite-modified human placental DNA (Sigma, Egyptial International Center for Import Cairo, Egypt) and CpGenome universal methylated human DNA (Intergen Co, New York, NY) served as negative and positive control, respectively. The PCR products were separated with 2.2% agarose gel electrophoresis and visualized with 0.1% ethidium bromide staining.
2.7
Statistical analysis
Statistical analyses were performed using the SPSS version 17 for Windows (SPSS Inc, Chicago, IL) program package. The 2-sided χ 2 test was used to compare categorical variables, if the sample size was large. Fischer exact test was used when the sample size was small; such test was used when comparing the associations of hMLH1 immunoreactivity with age and sex. P ≤ .05 was used as a significance criterion.